Drug Interactions & Polypharmacy

A patient's medications each look safe individually — but together, one silently doubles the blood level of another. Recognizing how drugs alter each other is how you prevent the harm no one ordered.

Drug interactions occur through three main mechanisms: pharmacokinetic (one drug changes how another is absorbed, distributed, metabolized, or excreted), pharmacodynamic (two drugs amplify or oppose each other's effect at the target site), and pharmaceutical (physical/chemical incompatibility, such as mixing IV drugs that precipitate). The most clinically tested pharmacokinetic pathway involves cytochrome P450 liver enzymes. An inhibitor (e.g., erythromycin, grapefruit juice, fluconazole) slows metabolism of a second drug, raising its serum level toward toxicity. An inducer (e.g., carbamazepine, rifampin, St. John's Wort) speeds metabolism, potentially dropping a drug below therapeutic range. Polypharmacy — typically defined as concurrent use of five or more medications — disproportionately increases interaction risk, especially in older adults with declining renal and hepatic function. Nursing responsibility centers on reviewing the full medication list (including OTCs, herbals, and supplements) at every encounter, monitoring for unexpected changes in drug effect, and reporting signs of toxicity or subtherapeutic response promptly.

Key Distinctions

Don't confuse additive effects (1+1=2, e.g., two CNS depressants causing oversedation) with synergistic effects (1+1=3, amplification beyond simple addition). Students often mistake a CYP450 inhibitor for an inducer — remember inhibitors increase drug levels (risk of toxicity), inducers decrease them (risk of therapeutic failure). Pharmaceutical incompatibility is a mixing problem, not a body problem — it happens in the IV tubing, not in the patient.

Clinical Pearl

Inhibitors Increase levels, Inducers decrease them. Think 'I-I' pair: Inhibitor = Increase. Rifampin is the classic inducer — it revs the engine and burns drugs faster.